Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-1001 in CABG surgery for reduction of ischemia-reperfusion cardiac injury
2009-009657-19Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jun 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial ischemia-reperfusion injury and coronary arteriosclerosis comparing IK-1001 with Placebo (2 arms). Primary endpoints: Safety, Population pharmacokinetics and 3 more. Started Jun 2009; status: terminated.
02
Drugs
sodium sulfide
03
Conditions
myocardial ischemia-reperfusion injurycoronary arteriosclerosis
Beyond the preview
Go deeper on 2009-009657-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009657-19.